https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2024-0010
Announcing a new publication for Acta Materia Medica journal. Proteolysis targeting chimeras (PROTACs), as a novel therapeutic drug model, has received widespread attention from academia and the pharmaceutical industry. PROTAC technology has led researchers to focus on developing chemical biology tool properties due to the unique operating mechanism and protein dynamic regulatory properties. In recent years the rapid development of PROTAC technology has gradually made PROTACs an essential tool for target identification and validation. To further promote the application of PROTAC tools in drug discovery and basic medical science research, this article distinguishes target identification and validation concepts. Furthermore, research progress in PROTAC technology is summarized.
# # # # # #
Acta Materia Medica welcomes the submission of research articles, review articles, databases, mini reviews, commentaries, editorials, short communications, case report articles and study protocols.
Submission Process
Submissions to Acta Materia Medica are made using ScholarOne, the online submission and peer review system. Registration and access are available at https://mc04.manuscriptcentral.com/ammed
Queries about the journal can be sent to editorialoffice@amm-journal.org .
Please visit https://amm-journal.org/ to learn more about the journal.
Editorial Board: https://amm-journal.org/index.php/editorial-board/
There are no author submission or article processing fees.
Follow Acta Materia Medica on Twitter https://twitter.com/AMM_journal ; Facebook ( https://www.facebook.com/AMMjournal )
eISSN 2737-7946
Yang Liu, Jing Liang and Rui Zhu et al. Application of PROTACs in target identification and validation. Acta Materia Medica. 2024. Vol. 3(1):72-87. DOI: 10.15212/AMM-2024-0010
Acta Materia Medica